A Randomized, Controlled, Double-blind Study to Evaluate Efficacy and Survival of Combining Nimotuzumab Plus Concurrent Chemo-radiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma

Trial Profile

A Randomized, Controlled, Double-blind Study to Evaluate Efficacy and Survival of Combining Nimotuzumab Plus Concurrent Chemo-radiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Apr 2016

At a glance

  • Drugs Nimotuzumab (Primary) ; Cisplatin; Paclitaxel
  • Indications Oesophageal cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Apr 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 08 Apr 2015 New trial record
    • 07 Apr 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top